Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
18.08
-0.13 (-0.69%)
Feb 26, 2026, 4:00 PM EST - Market closed
Corvus Pharmaceuticals Analyst Ratings
Total Analysts
5
Consensus Rating
Strong Buy
Price Target
$28.00
Upside
+54.91%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy Maintains $13 → $42 | Strong Buy | Maintains | $13 → $42 | +132.37% | Jan 22, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $15 → $32 | Buy | Maintains | $15 → $32 | +77.04% | Jan 21, 2026 |
| Barclays | Barclays | Buy Maintains $16 → $28 | Buy | Maintains | $16 → $28 | +54.91% | Jan 21, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $11 → $27 | Strong Buy | Maintains | $11 → $27 | +49.38% | Jan 20, 2026 |
| Barclays | Barclays | Buy Initiates $16 | Buy | Initiates | $16 | -11.48% | Oct 13, 2025 |
| Mizuho | Mizuho | Buy Maintains $12 → $11 | Buy | Maintains | $12 → $11 | -39.14% | May 20, 2025 |
| Oppenheimer | Oppenheimer | Buy Reiterates $15 → $17 | Buy | Reiterates | $15 → $17 | -5.95% | May 9, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $14 → $15 | Buy | Maintains | $14 → $15 | -17.01% | Mar 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | -39.14% | Mar 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $11 | Strong Buy | Reiterates | $11 | -39.14% | Jan 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | -39.14% | Jan 2, 2025 |
| Oppenheimer | Oppenheimer | Buy Reiterates $8 → $14 | Buy | Reiterates | $8 → $14 | -22.54% | Nov 13, 2024 |
| Mizuho | Mizuho | Hold → Buy Upgrades $3.5 → $12 | Hold → Buy | Upgrades | $3.5 → $12 | -33.61% | Oct 22, 2024 |
| Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Maintains $12 → $21 | Strong Buy | Maintains | $12 → $21 | +16.18% | Sep 16, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $7 → $8 | Buy | Maintains | $7 → $8 | -55.74% | May 7, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Apr 1, 2024 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.